Empower Your Fight Against Prostate Cancer
Prostate cancer is uniquely driven by androgen signaling. Learn why preventing your tissue from being discarded allows access to next-generation mapping when standard hormone therapies fail.
Talk to a Care SpecialistWhat is Prostate Cancer?
Prostate cancer originates in the prostate gland and is typically driven by male sex hormones (androgens) like testosterone. It is often slow-growing initially but can unpredictably transform into an aggressive state.
When the cancer mutates to survive even when testosterone is medically stripped from the body—a state known as Castration-Resistant Prostate Cancer (CRPC)—cutting-edge targeted science becomes essential.
What Does Prostate Cancer Do?
The tumor impacts local urological function before establishing painful systemic metastases.
- Urinary Obstruction: The expanding prostate heavily compresses the urethra, severely disrupting bladder emptying.
- Osteoblastic Bone Metastases: Prostate cancer uniquely forms brittle, dense lesions in the spine and pelvis, causing significant pain.
- Systemic Endocrine Strain: The systemic treatments required to starve the cancer of hormones create dramatic metabolic and physical shifts.
Current Treatment Options
Radical Prostatectomy
The complete surgical removal of the prostate gland and surrounding tissues, generating significant amounts of tissue.
Androgen Deprivation Therapy (ADT)
Medical or surgical castration intended to drop testosterone to near-zero, starving the tumor of its primary fuel.
Radioligand Therapy
Precision nuclear medicine (like Pluvicto) that seeks out the PSMA protein on prostate cells to deliver a radioactive payload directly.
Why Bank Your Living Prostate Tissue?
Prostate tumors that enter the castration-resistant phase are extraordinarily resilient. Living tissue is required to identify if your cancer has developed neuroendocrine features or actionable DNA repair mutations (like BRCA) that unlock distinct clinical protocols.
Novel Pathway Screening
Test off-body if next-generation hormone receptor blockers will successfully navigate your tumor's resistance mechanisms.
DNA Repair Defect Analysis
Maintain pristine cellular DNA to test eligibility for PARP inhibitors, a revolutionary class of targeted therapies.
PSMA Verification
Cultured tissue verifies the density and presence of PSMA targets for upcoming advanced radioligand clinical trials.
Adaptive Growth Modeling
Simulating your tumor's growth allows researchers to map out multi-step combination therapies before they hit your body.